ABSTRACT
ABSTRACT: Hemoglobin Bart's hydrops fetalis syndrome (BHFS) represents the most severe form of α-thalassemia, arising from deletion of the duplicated α-globin genes from both alleles. The absence of α-globin leads to the formation of nonfunctional hemoglobin (Hb) Bart's (γ4) or HbH (ß4) resulting in severe anemia, tissue hypoxia, and, in some cases, variable congenital or neurocognitive abnormalities. BHFS is the most common cause of hydrops fetalis in Southeast Asia; however, owing to global migration, the burden of this condition is increasing worldwide. With the availability of intensive perinatal care and intrauterine transfusions, an increasing number of patients survive with this condition. The current approach to long-term management of survivors involves regular blood transfusions and iron chelation, a task made challenging by the need for intensified transfusions to suppress the production of nonfunctional HbH-containing erythrocytes. Although our knowledge of outcomes of this condition is evolving, it seems, in comparison to individuals with transfusion-dependent ß-thalassemia, those with BHFS may face an elevated risk of complications arising from chronic anemia and hypoxia, ongoing hemolysis, iron overload, and from their respective treatments. Although stem cell transplantation remains a viable option for a select few, it is not without potential side effects. Looking ahead, potential advancements in the form of genetic engineering and innovative therapeutic approaches, such as the reactivation of embryonic α-like globin gene expression, hold promise for furthering the treatment of this condition. Prevention remains a crucial aspect of care, particularly in areas with high prevalence or limited resources.
Subject(s)
Hemoglobins, Abnormal , Hydrops Fetalis , alpha-Thalassemia , Humans , Hydrops Fetalis/genetics , Hydrops Fetalis/therapy , Hydrops Fetalis/etiology , Hydrops Fetalis/diagnosis , Hemoglobins, Abnormal/genetics , alpha-Thalassemia/genetics , alpha-Thalassemia/therapy , alpha-Thalassemia/diagnosis , PregnancyABSTRACT
Thromboembolism is an infrequent complication in children with hemophilia that has been traditionally associated with the presence of a central venous access device. Novel rebalancing agents have shown promising results as prophylactic therapies to minimize the risk of bleeding but both thromboembolism and thrombotic microangiopathy have been reported as complications. The management of thrombosis in children with hemophilia is particularly challenging given the inherent risk of bleeding. In this paper, we present clinical vignettes to review the literature, highlight challenges, and describe our approach to managing thromboembolism in children with hemophilia.
ABSTRACT
Owing to the unique pathophysiology of anaemia in haemoglobin Bart's hydrops fetalis (HBHF), a transfusion strategy based on beta-thalassemia guidelines is suboptimal for chronically transfused HBHF patients. A more aggressive transfusion aimed at reducing the proportion of non-functional HbH and improving the "functional" haemoglobin (f-Hb) can lead to reduced haemolysis and improved tissue oxygenation. However, the optimal transfusion targets for these parameters are not yet defined. In this retrospective, longitudinal study on four chronically transfused patients with HBHF, we used receiver operating characteristic curves to find a pre-transfusion f-Hb of 106 g/l and a HbH of 16.1% to be the optimal thresholds to achieve a normal soluble transferrin receptor and lactate dehydrogenase, respectively.
Subject(s)
Hemoglobins, Abnormal , alpha-Thalassemia , Female , Hemoglobin H , Humans , Hydrops Fetalis/therapy , Longitudinal Studies , Pregnancy , Prenatal Diagnosis , Retrospective Studies , Survivors , alpha-Thalassemia/therapyABSTRACT
OBJECTIVES: With improved access to intrauterine transfusion (IUT), more fetuses with haemoglobin Bart's hydrops fetalis (HBHF; homozygous α0-thalassaemia) will survive. DESIGN: To evaluate the long-term outcome of affected fetuses with and without IUT in Ontario, Canada, we retrospectively collected data on IUTs and pregnancy outcomes in all cases of HBHF, from 1989 to 2014. Clinical outcome and neurocognitive profiles of long-term survivors were also collected and compared with data from 24 patients with transfusion-dependent ß-thalassaemia (TDT-ß). RESULTS: Of the 99 affected pregnancies (93 prenatally diagnosed), 68 resulted in miscarriage or elective termination of pregnancy. Twelve mothers (12%) continued their pregnancies without IUT, and none of those newborns survived the first week of life. All 13 fetuses that received IUT(s) were live-born, but 3 died due to severe hydrops at birth and 1 died due to infection. The remaining nine survivors, in comparison with TDT-ß patients, had earlier iron overload requiring iron chelation therapy. Endocrinopathies and short stature were more frequent in these patients. Neurocognitive outcome was not significantly affected in five patients who were assessed, and none were diagnosed with intellectual impairment. In three patients, MRI studies demonstrated brain white matter changes in keeping with 'silent' ischaemic infarcts. CONCLUSIONS: In patients with HBHF, IUT is associated with improved survival. While acceptable neurocognitive outcome can be expected, these patients have more clinical complications compared with their TDT-ß counterparts. The clinical and neurocognitive outcomes of HBHF should be discussed in detail when counselling and offering IUT for patients.
Subject(s)
Blood Transfusion, Intrauterine/methods , Hemoglobins, Abnormal/metabolism , Hydrops Fetalis/physiopathology , Hydrops Fetalis/therapy , Abortion, Induced/statistics & numerical data , Abortion, Spontaneous/epidemiology , Female , Humans , Hydrops Fetalis/mortality , Iron Overload/epidemiology , Ontario , Pregnancy , Prenatal Diagnosis , Retrospective Studies , Severity of Illness IndexABSTRACT
Hereditary spherocytosis (HS) is a common inherited haemolytic anaemia and has great variability in its presentation. Non-transfusion iron overload in HS has only been reported with co-inheritance of hereditary haemochromatosis (HHC). We present 4 unrelated patients of East Asian ethnicity with mild HS and significant non-transfusion iron overload in the absence of known disease-causing mutations in HHC genes. We hypothesise that, in patients with mild HS, life-long chronic haemolysis and erythropoietic drive may promote iron absorption. This suggests that mild HS may not be entirely benign, and that patients with mild HS should be monitored for iron overload.
Subject(s)
Erythropoiesis , Hemochromatosis , Hemolysis , Iron Overload , Mutation , Spherocytosis, Hereditary , Adolescent , Adult , Asian People , Asia, Eastern , Female , Hemochromatosis/blood , Hemochromatosis/genetics , Humans , Iron Overload/blood , Iron Overload/genetics , Male , Spherocytosis, Hereditary/blood , Spherocytosis, Hereditary/geneticsABSTRACT
BACKGROUND: Little is known about severe pulmonary embolism in children. We aimed to report pulmonary embolism outcomes, identify risk factors for unfavourable outcomes, and evaluate the discriminative ability of two clinical-severity indices in children. METHODS: In this retrospective cohort study, we included consecutive patients aged 18 years or younger with acute pulmonary embolism, objectively diagnosed radiologically or pathologically, between Jan 1, 2000, and Dec 31, 2016, from two Canadian paediatric hospitals (The Hospital for Sick Children, Toronto, ON, and the Children's Hospital of Eastern Ontario, Ottawa, ON). Exclusion criteria were sudden death without radiological or pathological pulmonary embolism confirmation and non-thromboembolic pulmonary embolism. The primary outcome was a composite of unfavourable outcomes of pulmonary embolism-related death and pulmonary embolism recurrence or progression. Potential predictors of the composite unfavourable outcome (ie, age at pulmonary embolism diagnosis, sex, underlying cardiac disease, severity of the pulmonary embolism, presence of a central venous catheter, associated venous thromboembolism, family history of thrombosis, treatment modalities, thrombophilia, obesity, and recent surgery) were explored with logistic regression. We calculated pulmonary embolism severity index (PESI) and simplified PESI (sPESI) using age-adjusted parameters; we estimated the ability of PESI and sPESI to predict mortality using receiver-operating characteristic (ROC) curve analysis. FINDINGS: Of the 170 patients included, 37 (22%) had massive, 12 (7%) submassive, and 121 (71%) non-massive pulmonary embolism. Patients with massive or submassive pulmonary embolism were younger (median age 12·5 years [IQR 0·6-15·1] vs 14·4 years [9·3-16·1], p<0·0001), more likely to have a cardiac condition (16 [33%] vs 17 [14%] patients, p=0·009), and had more central venous catheters (29 [59%] vs 48 [40%] patients, p=0·027) than patients with non-massive pulmonary embolism. Aggressive treatment modalities were more commonly used in massive or submassive pulmonary embolism (22 [45%] vs 7 [6%] patients, p<0·0001). Of the predictors tested, only pulmonary embolism severity was associated with the composite unfavourable outcome in the multivariable analysis (odds ratio 3·53, 95% CI 1·69-7·36; p=0·011). The area under the ROC curve for PESI to predict 30-day mortality was 0·76 (95% CI 0·64-0·87). Sensitivity of sPESI was 100% and specificity was 30%. INTERPRETATION: Massive or submassive pulmonary embolism led to higher rates of unfavourable outcomes than non-massive pulmonary embolism in children. Further adaptations of PESI and sPESI are required to improve their clinical usefulness in paediatric patients. FUNDING: Trainee Start-Up Fund (The Hospital for Sick Children).
Subject(s)
Pulmonary Embolism/diagnosis , Adolescent , Child , Child, Preschool , Female , Humans , Male , Prognosis , ROC Curve , Retrospective Studies , Risk FactorsSubject(s)
Blood Transfusion/statistics & numerical data , Hemoglobins, Abnormal , Hydrops Fetalis/therapy , Iron Overload/epidemiology , Survivors/statistics & numerical data , Canada/epidemiology , Child , Female , Follow-Up Studies , Humans , Iron Overload/pathology , Longitudinal Studies , Male , Prognosis , Retrospective Studies , beta-Thalassemia/therapySubject(s)
Blood Transfusion/methods , Hemoglobins, Abnormal/metabolism , Hydrops Fetalis/therapy , Survivors , Adolescent , Child , Erythropoiesis , Female , Homozygote , Humans , MaleABSTRACT
Over the past few decades, there has been a remarkable improvement in the survival of patients with thalassaemia in developed countries. Availability of safe blood transfusions, effective and accessible iron chelating medications, the introduction of new and non-invasive methods of tissue iron assessment and other advances in multidisciplinary care of thalassaemia patients have all contributed to better outcomes. This, however, may not be true for patients who are born in countries where the resources are limited. Unfortunately, transfusion-transmitted infections are still major concerns in these countries where paradoxically thalassaemia is most common. Moreover, oral iron chelators and MRI for monitoring of iron status may not be widely accessible or affordable, which may result in poor compliance and suboptimal iron chelation. All of these limitations will lead to reduced survival and increased thalassaemia-related complications and subsequently will affect the patient's quality of life. In countries with limited resources, together with improvement of clinical care, strategies to control the disease burden, such as public education, screening programmes and appropriate counselling, should be put in place. Much can be done to improve the situation by developing partnerships between developed countries and those with limited resources. Future research should also particularly focus on patient's quality of life as an important outcome of care.
Subject(s)
Quality of Health Care , Quality of Life , Thalassemia/therapy , Child , Erythrocyte Transfusion , Humans , Iron Chelating Agents/therapeutic use , Iron Overload/etiology , Stem Cell Transplantation , Thalassemia/complications , Thalassemia/epidemiology , Thalassemia/physiopathologyABSTRACT
Differentiating between ß-thalassemia (ß-thal) minor and iron deficiency has important implications in thalassemia carrier screening. Several complete blood count (CBC)-based equations have been proposed for differentiating these two conditions. The applicability of these equations in populations with high rates of iron deficiency and ß-thal minor, where patients can have both conditions, is limited. In addition, there have been conflicting reports on the possible effect of iron deficiency on Hb A2 level with possible consequences for thalassemia screening programs. Here, we demonstrate that in our population the Mentzer Index separates individuals with ß-thal minor from those without ß-thal minor, regardless of their iron status. Iron deficiency also does not reduce Hb A2 levels in ß-thal minor patients. Correction of iron deficiency is not required for diagnosis of ß-thal minor using high performance liquid chromatography (HPLC).
Subject(s)
Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/epidemiology , Thalassemia/complications , Thalassemia/epidemiology , Adolescent , Anemia, Iron-Deficiency/diagnosis , Child , Child, Preschool , Erythrocyte Indices , Female , Hemoglobin A2/metabolism , Heterozygote , Humans , Male , Mass Screening , Mutation , Population Surveillance , Thalassemia/diagnosis , Thalassemia/genetics , beta-Globins/genetics , beta-Thalassemia/complications , beta-Thalassemia/diagnosis , beta-Thalassemia/epidemiology , beta-Thalassemia/geneticsSubject(s)
Anemia, Sickle Cell/genetics , Hemoglobin, Sickle/genetics , Locus Control Region , Sequence Deletion , beta-Globins/genetics , beta-Thalassemia/genetics , Anemia, Sickle Cell/diagnosis , Base Sequence , Child , Chromosome Mapping , Genetic Association Studies , Heterozygote , Humans , Male , Molecular Sequence Data , Multigene Family , Mutation , Phenotype , beta-Thalassemia/diagnosisABSTRACT
Over the past decades there has been a significant improvement in the care of patients with sickle cell disease (SCD) in high-income countries. However, more needs to be learned about the complex pathophysiology and the factors that contribute to the development of end organ damage from the disease. While antibiotic prophylaxis and appropriate treatment of infections have resulted in a significant reduction of early mortality, management of the painful episodes and prevention of organ damage remain a challenge. Hydroxyurea is the only medication approved as disease-modifying therapy, and bone marrow transplant as curative treatment is not available to most patients. In low-income countries with the highest disease burden, early mortality is high due to limited resources for systematic screening, early diagnosis, and disease management. In order to improve outcomes in patients with SCD in high-income countries, better and widespread implementation of known disease-modifying therapies and the development of newer therapies targeting key pathophysiologic pathways are required. In low-income countries with high disease burden, innovative approaches to develop low-cost diagnostic devices and treatments that can be implemented to scale are needed to combat early mortality from the disease. Sustainable solutions in low-resource settings require evidence-based affordable interventions that can be integrated into primary and secondary healthcare systems.